Alpha DNA Investment Management LLC Has $450,000 Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA)

Alpha DNA Investment Management LLC decreased its stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 56.0% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 40,277 shares of the biotechnology company’s stock after selling 51,347 shares during the period. Alpha DNA Investment Management LLC’s holdings in ADMA Biologics were worth $450,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in the stock. Quest Partners LLC bought a new stake in ADMA Biologics during the 2nd quarter valued at approximately $29,000. EntryPoint Capital LLC bought a new position in ADMA Biologics during the first quarter worth $31,000. CWM LLC raised its stake in ADMA Biologics by 114.2% during the 2nd quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock valued at $92,000 after purchasing an additional 4,367 shares during the last quarter. Acadian Asset Management LLC bought a new stake in ADMA Biologics in the 2nd quarter valued at $93,000. Finally, Viewpoint Capital Management LLC grew its position in ADMA Biologics by 18.6% in the 1st quarter. Viewpoint Capital Management LLC now owns 15,416 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 2,416 shares during the last quarter. Institutional investors and hedge funds own 75.68% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. Mizuho boosted their price objective on shares of ADMA Biologics from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Thursday, June 20th. HC Wainwright boosted their price objective on shares of ADMA Biologics from $10.00 to $18.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $20.00 price objective on shares of ADMA Biologics in a report on Friday, September 20th. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, ADMA Biologics currently has a consensus rating of “Buy” and an average price target of $15.50.

ADMA Biologics Trading Up 1.0 %

ADMA opened at $19.49 on Thursday. The firm’s fifty day moving average is $16.14 and its two-hundred day moving average is $11.24. The company has a debt-to-equity ratio of 0.74, a quick ratio of 2.80 and a current ratio of 6.87. The firm has a market cap of $4.54 billion, a PE ratio of -974.50 and a beta of 0.61. ADMA Biologics, Inc. has a twelve month low of $3.06 and a twelve month high of $20.16.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings data on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.05. ADMA Biologics had a net margin of 10.53% and a return on equity of 38.79%. The company had revenue of $107.20 million during the quarter, compared to the consensus estimate of $86.44 million. During the same quarter in the prior year, the firm earned ($0.02) earnings per share. The firm’s revenue was up 78.4% compared to the same quarter last year. Equities research analysts anticipate that ADMA Biologics, Inc. will post 0.49 EPS for the current year.

Insider Activity at ADMA Biologics

In related news, Director Lawrence P. Guiheen sold 9,000 shares of the firm’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $18.47, for a total value of $166,230.00. Following the completion of the transaction, the director now owns 153,941 shares of the company’s stock, valued at $2,843,290.27. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other ADMA Biologics news, Director Lawrence P. Guiheen sold 9,000 shares of the stock in a transaction on Monday, September 9th. The shares were sold at an average price of $18.47, for a total value of $166,230.00. Following the completion of the sale, the director now owns 153,941 shares in the company, valued at $2,843,290.27. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Young Kwon sold 60,000 shares of the stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $18.26, for a total transaction of $1,095,600.00. Following the completion of the sale, the director now owns 241,441 shares of the company’s stock, valued at approximately $4,408,712.66. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 466,900 shares of company stock valued at $8,224,121. Corporate insiders own 3.70% of the company’s stock.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.